Screener
Amneal Pharmaceuticals, Inc. AMRX Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Inventory provision | 44,957 | 38,432 |
| Other operating charges and credits, net | 3,086 | 2,254 |
| Changes in assets and liabilities: | ||
| Trade accounts receivable, net | (125,765) | (32,615) |
| Inventories | (124,150) | (36,039) |
| Prepaid expenses, other current assets and other assets | (24,150) | (10,015) |
| Related party receivables | 25 | (1,108) |
| Accounts payable, accrued expenses and other liabilities | (57,918) | (67,004) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s accounts receivable?
- Amneal Pharmaceuticals, Inc. (AMRX) reported accounts receivable of $169.78M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s accounts receivable changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s accounts receivable increased by 215.8% year-over-year, from $53.76M to $169.78M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s accounts receivable?
- Over 5 years (2020 to 2025), Amneal Pharmaceuticals, Inc.'s accounts receivable has grown at a -56.2% compound annual growth rate (CAGR), from $638.9M to $10.34M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Amneal Pharmaceuticals, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude